Login to Your Account

Financings Roundup

Late-Stage Cancer Vaccine Firm NewLink Files for $86M IPO

By Jennifer Boggs

Wednesday, December 22, 2010
NewLink Genetics Corp. became the latest biotech to jump into the initial public offering (IPO) queue, with a filing that looks to raise as much as $86 million to help fund its ongoing Phase III study in pancreatic cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription